Detalles de la búsqueda
1.
Efficacy of Bezlotoxumab in Trial Participants Infected With Clostridioides difficile Strain BI Associated With Poor Outcomes.
Clin Infect Dis;
73(9): e2616-e2624, 2021 11 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32735653
2.
Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: 12-Month Observational Data From the Randomized Phase III Trial, MODIFY II.
Clin Infect Dis;
71(4): 1102-1105, 2020 08 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-31883370
3.
Effect of Endogenous Clostridioides difficile Toxin Antibodies on Recurrence of C. difficile Infection.
Clin Infect Dis;
71(1): 81-86, 2020 06 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-31628838
4.
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.
N Engl J Med;
376(4): 305-317, 2017 01 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-28121498
5.
A randomized, double-blind trial investigating the efficacy of caspofungin versus amphotericin B deoxycholate in the treatment of invasive candidiasis in neonates and infants younger than 3 months of age.
J Antimicrob Chemother;
75(1): 215-220, 2020 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31586424
6.
Analysis of C. difficile infection-related outcomes in European participants in the bezlotoxumab MODIFY I and II trials.
Eur J Clin Microbiol Infect Dis;
39(10): 1933-1939, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-32504314
7.
A time-to-event analysis of the exposure-response relationship for bezlotoxumab concentrations and CDI recurrence.
J Pharmacokinet Pharmacodyn;
47(2): 121-130, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32048107
8.
Bezlotoxumab for prevention of Clostridium difficile infection recurrence: Distinguishing relapse from reinfection with whole genome sequencing.
Anaerobe;
61: 102137, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31846705
9.
Population Pharmacokinetics and Pharmacodynamics of Bezlotoxumab in Adults with Primary and Recurrent Clostridium difficile Infection.
Antimicrob Agents Chemother;
63(2)2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30455246
10.
Cost-effectiveness of Bezlotoxumab Compared With Placebo for the Prevention of Recurrent Clostridium difficile Infection.
Clin Infect Dis;
66(3): 355-362, 2018 01 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-29106516
11.
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.
Clin Infect Dis;
67(5): 649-656, 2018 08 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-29538686
12.
Efficacy of bezlotoxumab based on timing of administration relative to start of antibacterial therapy for Clostridium difficile infection.
J Antimicrob Chemother;
73(9): 2524-2528, 2018 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29788418
13.
The effect of bezlotoxumab for prevention of recurrent Clostridium difficile infection (CDI) in Japanese patients.
J Infect Chemother;
24(2): 123-129, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29097028
14.
Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection.
Clin Infect Dis;
65(7): 1218-1221, 2017 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30060024
15.
Antibodies to Toxin B Are Protective Against Clostridium difficile Infection Recurrence.
Clin Infect Dis;
63(6): 730-734, 2016 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27365387
16.
Bezlotoxumab and Recurrent Clostridium difficile Infection.
N Engl J Med;
376(16): 1594-6, 2017 04 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-28423298
17.
Bezlotoxumab for Clostridium difficile Infection Complicating Inflammatory Bowel Disease.
Gastroenterology;
155(4): 1270-1271, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30227108
18.
Double-Blind, Placebo-Controlled Study of Bezlotoxumab in Children Receiving Antibacterial Treatment for Clostridioides difficile Infection (MODIFY III).
J Pediatric Infect Dis Soc;
12(6): 334-341, 2023 Jun 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-37389891
19.
Corrigendum to: Renal Impairment, C. difficile Recurrence, and the Differential Effect of Bezlotoxumab: A Post Hoc Analysis of Pooled Data From 2 Randomized Clinical Trials.
Open Forum Infect Dis;
8(1): ofaa629, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33511241
20.
Global Landscape of Clostridioides Difficile Phylogeography, Antibiotic Susceptibility, and Toxin Polymorphisms by Post-Hoc Whole-Genome Sequencing from the MODIFY I/II Studies.
Infect Dis Ther;
10(2): 853-870, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33751421